IRONWOOD PHARMACEUTICALS, INC. Sublease Income
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Sublease Income of $300.00 thousand for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SubleaseIncome · last filed 2022-02-18
- IRONWOOD PHARMACEUTICALS, INC. sublease income for the quarter ending 2020-09-30 was $300.00K.
- IRONWOOD PHARMACEUTICALS, INC. sublease income for the quarter ending 2019-12-31 was $0.00.
- IRONWOOD PHARMACEUTICALS, INC. sublease income for the quarter ending 2019-09-30 was $0.00.
- IRONWOOD PHARMACEUTICALS, INC. sublease income for the quarter ending 2019-06-30 was $300.00K.
- IRONWOOD PHARMACEUTICALS, INC. sublease income for fiscal 2019 was $300.00K.
| Period end | Sublease Income 3 month | Sublease Income 6 month | Sublease Income 9 month | Sublease Income 12 month |
|---|---|---|---|---|
| 2020-09-30 | $300.00K 10-Q · filed 2020-11-05 | $300.00K 10-Q · filed 2020-11-05 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $0.00 derived: sum of 2 quarters · filed 2022-02-18 | $300.00K derived: sum of 3 quarters · filed 2022-02-18 | $300.00K 10-K · filed 2022-02-18 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $300.00K derived: sum of 2 quarters · filed 2020-08-06 | $300.00K 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $300.00K 10-Q · filed 2020-08-06 | $300.00K 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |